What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.